COVID-19 therapeutics I: Initial clinical application studies, up-scaling and production of GMP material of the complement C5a inhibitor AON-D21 for proof-of-concept in COVID-19 patients (Accelerate-D21)
- Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
- Total publications:0 publications
Grant number: 16LW0006
Grant search
Key facts
Disease
COVID-19Start & end year
20212023Known Financial Commitments (USD)
$6,216,270.65Funder
Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)Principal Investigator
N/A
Research Location
GermanyLead Research Institution
Aptarion Biotech AGResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable